Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 815,949 |
|
|||||
| News | - | ||||||
| Day High | 1.95 | Low High |
|||||
| Day Low | 1.80 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adicet Bio Inc | ACET | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.045 | -2.40% | 1.83 | 19:52:06 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.895 | 1.80 | 1.95 | 1.81 | 1.875 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,004 | 815,949 | $ 1.85 | $ 1,508,562 | - | 1.10 - 7.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:52:06 | formt | 782 | $ 1.83 | USD |
Adicet Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 98.42M | 43.16M | - | 0 | -142.66M | -3.31 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Adicet Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACET Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.29 | 2.29 | 1.80 | 1.98 | 918,148 | -0.46 | -20.09% |
| 1 Month | 2.33 | 2.43 | 1.80 | 2.17 | 667,301 | -0.50 | -21.46% |
| 3 Months | 3.00 | 3.62 | 1.80 | 2.48 | 1,293,355 | -1.17 | -39.00% |
| 6 Months | 1.31 | 3.77 | 1.10 | 2.47 | 1,133,286 | 0.52 | 39.69% |
| 1 Year | 6.08 | 7.50 | 1.10 | 2.64 | 898,002 | -4.25 | -69.90% |
| 3 Years | 14.42 | 21.87 | 1.10 | 8.26 | 650,481 | -12.59 | -87.31% |
| 5 Years | 14.98 | 21.87 | 1.10 | 8.47 | 561,291 | -13.15 | -87.78% |
Adicet Bio Description
| Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. |
